Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms reaffirming their positive outlook on the biotech company.
BTIG analyst Justin Zelin reiterated a Buy rating on Enliven Therapeutics early Thursday, setting an ambitious price target of $45.00. This target suggests significant upside potential from the stock's previous closing price of $19.99. Additionally, TD Cowen analyst Phil Nadeau maintained his Buy rating on the company in a report released late Wednesday.
The back-to-back bullish ratings from respected analysts appear to have boosted investor confidence in Enliven Therapeutics' prospects. As the biotech sector continues to attract attention, ELVN's strong pre-market performance indicates that market participants are responding positively to the analysts' optimistic views on the company's future.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。